ArticleBeilstein journal of nanotechnology2025
Development of a mucoadhesive drug delivery system and its interaction with gastric cells.
Article in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epstein-Barr virus-encoded microRNA-BART17-5p suppresses cell proliferation and metastasis by targeting CERK.PLoS pathogens · 2026Article
- pH-Sensitive Dextrin-Based Nanosponges Crosslinked with Pyromellitic Dianhydride and Citric Acid: Swelling, Rheological Behavior, Mucoadhesion, and In Vitro Drug Release.Gels (Basel, Switzerland) · 2026Article
- Design and Characterization of Novel Gastroretentive Drug Delivery System of Antibiotics and Piperine for the Eradication ofMolecular pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs that are designed for local treatment of gastric diseases require increased gastric residence time for prolonged action and increased efficacy. In this study, we report a mucoadhesive drug delivery system that was developed to fulfill these requirements. Alginate nanoparticles were synthesized by water-in-oil emulsification followed by external gelation and then coated with the mucoadhesive polymer Eudragit RS100. The formulated nanoparticles had a mean size of 219 nm and positive charge. A peptide, as a model drug, was loaded onto the nanoparticles with an encapsulation efficiency of 58%. The release of the model drug from the delivery system was pH-independent and lasted for 7 days. The periodic acid-Schiff stain assay indicated 69% mucin interaction for the nanoparticles, which were also capable of diffusion through artificial mucus. The nanoparticles were not toxic to gastric epithelial cells and can be internalized by the cells within 4 h. The adsorption of nanoparticles onto mucus-secreting gastric cells was found to be correlated with cell number. The delivery system developed in this study is intended to be loaded with active therapeutic agents and has the potential to be used as an alternative drug delivery strategy for the treatment of gastric related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.